Home | Links | Contact Us | More About Intellectual Property | Bookmark
Search patents:
Home Quantum Computing Gamma-emitting-CCK-A-antagonists-for-pancreatic-imaging

 Macrocyclic polyamines
OF THE INVENTION Macrocyclic polyamines which form stable complexes with metal ions are known. The ...


 Fishing lure retriever
The embodiments of the invention in which an exclusive property or privilege is claimed are defined ...


 Magnetic resonance imaging agents
OF THE INVENTION The complexing agents employed in this invention are derivatives of well-known ...


 Method for detecting and locating inflammatory or tumor foci in a patient and diagnostic kit therefor
We claim: 1. A method for detecting and locating any inflammatory and/or tumor foci in a patient ...


 Extended lifetime railgap switch
I claim: 1. In a railgap switch of the type having an elongate blade electrode made of conductive ...


 Interhalogen based combustion-driven laser which provides continuous wave output lasing from dual species
Having thus described typical embodiments of my invention, that which I claim as new and desire to ...


 Data transmission system
Accordingly, the present invention has been devised with a view to substantially eliminating the ...


 Iodine gas laser device
The present invention provides an iodine laser comprising a tubular receptacle containing a gaseous ...


 Housing system for a laser
OF A PREFERRED EXAMPLE EMBODIMENT AND OF THE BEST MODE OF THE INVENTION A conventional wave-guide ...


 Cryogenic infrared laser in deuterium
In accordance with this invention, an infrared laser in deuterium is provided that lases in the 4 ....


 Gamma emitting, CCK-A antagonists for pancreatic imaging

Details
Inventors: Burns, H. Donald; Brenner, Nancy J.; Gibson, Raymond E.; Solomon, Howard F.;
Assignee: Merck & Co., Inc. (Rahway, NJ)
Primary Examiner: Maples; John S.
Assistant Examiner:
Attorney, Agent or Firm: Pfeiffer; Hesna J., Speer; Raymond M., Nicholson; William H.

Novel radiolabeled cholecystokinin-A (CCK-A) antagonists have been developed which, after intravenous injection, localize in the pancreas as a result of specific binding to CCK-A receptors. These tracers, when labeled with appropriate radiohalogens, are useful as commercial diagnostic imaging radiopharmaceuticals and radiotherapeutic drugs.

DETAILED DESCRIPTION OF THE INVENTION The present invention is directed toward radiolabelled compounds of Formula I: ##STR2## wherein: A is ##STR3## R.
sup.
1 is H, C.
sub.
1 -C.
sub.
6 linear or branched alkyl, (CH.
sub.
2).
sub.
n COOR.
sup.
8, (CH.
sub.
2).
sub.
n OH, (CH.
sub.
2).
sub.
n CN, (CH.
sub.
2).
sub.
n NR.
sup.
9 R.
sup.
10, ##STR4## R.
sup.
2 is H, --OH, --NO.
sub.
2, F, Cl, SO.
sub.
3 H, loweralkyl, loweralkoxy, (CH.
sub.
2).
sub.
p COOR.
sup.
8 or (CH.
sub.
2).
sub.
p NR.
sup.
9 R.
sup.
10 ; R.
sup.
3, is H, --OH, --NO.
sub.
2, CF.
sub.
3, F, Cl, loweralkyl, or loweralkoxy; R.
sup.
4 is H, --OH, --NO.
sub.
2, CF.
sub.
3, CN, F, Cl, loweralkyl, loweralkoxy, (CH.
sub.
2).
sub.
p COOR.
sup.
8 or (CH.
sub.
2).
sub.
p NR.
sup.
9 R.
sup.
10 ; R.
sup.
5, R.
sup.
6 and R.
sup.
7 are, independently, H or a radionuclide selected from the group consisting of .
sup.
122 I, .
sup.
123 I, .
sup.
125 I, .
sup.
131 I, .
sup.
75 Br, .
sup.
77 Br, .
sup.
82 Br, .
sup.
211 At, with the proviso that at least one of R.
sup.
5, R.
sup.
6 and R.
sup.
7 is not H; R.
sup.
8 is H or loweralkyl; R.
sup.
9 and R.
sup.
10 are, independently, H or loweralkyl; n is 1-4; m is 1-2; p is 0-4; or pharmaceutically acceptable salt thereof.
As used herein, the definition of each expression, e.
g.
m, n, p, loweralkyl, etc.
, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure.
In the compounds of the present invention, the components having asymmetric centers occur as racemates, racemic mixtures, and as individual diastereomers, with all isomeric forms generally being included in the present invention.
In particular, the preferred stereochemistry for CCK-A antagonism relates to D-tryptophan, where C-2 and N 4 of Formula I correspond to the carbonyl carbon and .
alpha.
-amino nitrogen of D-tryptophan and --NHCOA occupies the position of the indolylmethyl side chain.
As used herein, loweralkyl is 1-7 carbon straight or branched chain alkyl and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t butyl, sec-butyl, pentyl, hexyl, and heptyl; in loweralkoxy, the alkyl portion is lower alkyl as previously defined



Related patents
  Optical amplifying device
FIG. 2 illustrates one embodiment of an amplifying device 10 wherein the laser device 110 is surface emitting with a number of active regions forming a "total active ...
  Pharmaceutical delivery system
The present invention provides a method and means for dispensing in a controlled, continuous manner therapeutically effective amounts of water-soluble drugs for a ...
  Nitrogen-containing cyclic ligands
We claim: 1. A ligand having the formula: ##STR44## in which R.sub.1 represents a radical of the formula: ##STR45## R.sub.6 being selected from the group consisting of C....
  Conditioning shampoo
OF THE PREFERRED EMBODIMENT The conditioning shampoo composition of the preferred embodiment includes the following ingredients in the ranges, preferred ranges and best ...
  Methods of diagnostic image analysis using lipophilic contrast agents
OF THE INVENTION The present invention is directed to complexing acids and salts thereof which when combined with a paramagnetic, ferromagnetic or diamagnetic metal ion ...
  Method for increasing sensitivity to chemically induced terminal differentiation
OF THE INVENTION The present invention provides a method of selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation of ...
  Method for enhancing the safety of metal-ligand chelates as magnetic resonance imaging agents by addition of calcium ions
What is claimed is: 1. In a method for enhancing safety in the in vivo use of methal-ligand chelate complexes as magnetic resonance imaging agents comprising ...
  Hydrated biodegradable superparamagnetic metal oxides
OF THE INVENTION 1. Preparation of Coated Superparamagnetic Iron Oxide Particles The synthesis of superparamagnetic iron oxide particles for use as MRI contrast agents ...
  Halide-free process for the synthesis of ETS-10
OF THE INVENTION The present invention is directed towards crystalline titanium molecular sieve zeolites which have a pore size of approximately 8 Angstrom units and ...
  Compositions of iodophenoxy alkanes and iodophenyl ethers for visualization of the gastrointestinal tract
OF THE INVENTION Compounds of the present invention can be made according to the schematic procedure shown or other methods using commercially available starting ...

0.014

Archive: All patents - Links

Copyright (c)2006 Eipa-patents.org - All rights reserved